logo
'Postcode healthcare' persists - new report by government watchdog

'Postcode healthcare' persists - new report by government watchdog

RNZ News9 hours ago

The report said access to treatment was to a significant extent, determined by where a person lived. (File photo)
Photo:
UnSplash/ Marcelo Leal
Where you live (rather than how sick you are) is still a major factor in how quickly you get elective surgery - or whether you get it at all, according to a new report by the government watchdog.
The report, Providing equitable access to planned care, which has just been tabled in Parliament by the Auditor-General John Ryan, showed elective services in the public system were often "not equitable or timely", with people with the same level of clinical need qualifying for treatment in some districts, but not others.
"As a result, a person's ability to access treatment is, to a significant extent, determined by where they live," the report noted.
"Some clinical staff we spoke with were of the view that a lack of capacity to provide treatment had led to some thresholds that no longer reflect clinical need."
The Pae Ora (Healthy Futures) Act 2022 required Health New Zealand to ensure access to treatment (such as operations to remove cataracts or tonsils, joint replacements and hernia repairs) was based on people's clinical need - not their background, circumstances, or where they live.
However, the audit found Māori, Pacific peoples, people with disabilities, those living in rural areas or in poverty had worse access to planned care.
Health NZ was gradually introducing nationally consistent thresholds for ranking access to planned care.
"It has introduced a national threshold for cataract treatment. Work is under way to align other thresholds for orthopaedics, otorhinolaryngology (ear, nose, and throat conditions), and cardiology."
RNZ reported on Thursday, the
long wait times for ear, nose and throat services
in Tairāwhiti, which had less than a quarter of the specialist capacity needed.
Introducing a national threshold for cataract treatment had led to about 1800 people added to the waiting list in the Southern District and about 900 more people put on the waiting list in Counties Manukau, the new report found.
In orthopaedics, threshold "scores" for orthopaedic treatment range from 50 in Auckland and Canterbury to 80 in Wairarapa.
"This means that a person's condition needs to be significantly worse in Wairarapa than Canterbury or Auckland to qualify for treatment."
District-specific thresholds still in place were also "obscuring the extent of unmet need for treatment in some districts".
"Significant work will be required to deal with the changes in demand that will result from the introduction of nationally consistent thresholds across all specialities."
The true level of unmet need was unknown, the report continued.
"One possible measure of unmet need is the number of people who are assessed by a specialist but do not meet the threshold for treatment.
"However, we also heard some clinicians will not refer a person for specialist assessment if they are considered unlikely to meet the treatment threshold.
"Media reports during our audit suggested that specialities in some districts were not accepting referrals because they did not have the resources and would be
unable to meet target time frames for assessing or treating people."
Meeting the government's target for 95 percent of people receiving planned care treatment within four months by 2030 was going to require "significant improvement".
"During our audit, the latest available reporting (for October to December 2024) showed that about 59 percent of planned care patients received treatment within four months of being placed on a waiting list.
"The proportion of people receiving planned care treatment within four months has been in decline since 2017."
However, the focus on improving wait times should go hand-in-hand with a focus on equitable access, the report writers urged.
"Equity also needs to be a central consideration in Health NZ's work to improve timely provision of treatment. If this does not happen, there is a risk that
strategies to improve timeliness could cause further inequities."
Health was so interconnected, that too much focus in one area inevitably put pressure on the system elsewhere.
For instance, the number of patients waiting longer than one year for treatment was cut from more than 4000 in October 2023, to 1916 by July 2024, although it rose again to 2630 by December 2024.
However, in the same period, the waiting list for first specialist assessments nearly doubled, from 5000 to 9936, the auditors found.
Health Minister Simeon Brown's push for more outsourcing to private providers needed to be carefully managed so it did not lead to greater inequities, the Auditor-General said.
"Access to the private hospitals that provide outsourced treatment is not equally distributed across the country. This means that some districts can
outsource patients more easily and at shorter notice than others.
"In addition, not all patients can be outsourced for treatment. The people selected for outsourcing to private facilities are generally determined to be non-complex patients."
Māori and Pacific peoples and people living in socially deprived areas were also more likely to have complications, which would bar them from treatment in a private hospital.
"Health NZ needs to manage and monitor the outsourcing of treatment so that it does not compromise its focus on the treatment of patients in priority order or otherwise increase inequity in planned care."
Sign up for Ngā Pitopito Kōrero
,
a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Melatonin, ADHD medication and magic mushrooms - what are NZ's new changes in access to them?
Melatonin, ADHD medication and magic mushrooms - what are NZ's new changes in access to them?

RNZ News

time6 hours ago

  • RNZ News

Melatonin, ADHD medication and magic mushrooms - what are NZ's new changes in access to them?

Access to melatonin, psilocybin and ADHD treatment is changing. Photo: AFP / File / RNZ illustration Explainer - The government has changed regulations on several medications in the past fortnight. Here's what you need to know about melatonin, ADHD medicine and medicinal psilocybin access. Melatonin, which is used to treat sleeping problems, has up until now been tightly restricted in New Zealand, unlike many other countries. But it will soon be available over the counter at pharmacies, Associate Health Minister David Seymour said last week . It will be available in pharmacies as pills up to 5mg in packs with up to 10 days' supply, or pills up to 3mg. "Modified release doses" - pills, capsules, gels and medical devices which allow the drug to be administered over a specific period - could also be available with dosages of up to 2mg. Melatonin will remain prescription-only for children and adolescents , "following expert clinical advice to ensure proper oversight when used by younger patients," Seymour said. Melatonin is used to treat sleep disorders. Photo: Quin Tauetau/RNZ Melatonin is a hormone made by the pineal gland in your brain that helps regulate sleep cycles. It tends to decrease as we get older. Supplements are taken to help those with insomnia or other sleeping problems. "Most countries in the world allow you to buy it," Seymour said, noting Kiwis would often buy it on trips overseas and take it back home despite it being restricted here. "That makes no sense." One Auckland mother told RNZ recently that melatonin was "life saving" and a "game-changer" for her 10-year-old son with autism. Still, not everyone is convinced that it works. Studies have so far shown melatonin to be a "dud" in terms of effectiveness, Dr David Reith, an associate professor of pharmacology at the University of Otago, told RNZ last year. "The studies indicate it gets you to sleep 15 minutes quicker. But not that it keeps you asleep, improves the quality of your sleep, or increases the amount of time you sleep." Watch: David Seymour on changes to melatonin and psilocybin access It will take a little more time to see it on your chemist's shelf. Seymour said he called on the melatonin manufacturers of the world "to apply to bring their products into our country." "We are entirely dependent on the manufacturers to apply to have specific products available in New Zealand. The market dried up because it was so restricted nobody wanted to sell here. "But when we did this with pseudoephedrine it was a matter of months before the products were on the shelves and I hope we can beat that record." GPs and nurse practitioners will soon be able to diagnose and prescribe medications for attention-deficit hyperactivity disorder, or ADHD, to adults age 18 and over. The changes affect the stimulant medicines methylphenidate, dexamfetamine and lisdexamfetamine, also sold under various brand names. Medsafe and Pharmac announced the changes on Tuesday . Until now, it has required a written recommendation from a psychiatrist or paediatrician to start prescribing ADHD medications, a process which can take months. "I have heard stories of many people with ADHD who have been unable to get a diagnosis and treatment in a timely manner because of long wait items and costs associated with seeing a specialist," Mental Health Minister Matt Doocey said in announcing the change . Children and teenagers 17 and younger will be able to get prescriptions from nurse practitioners who work in mental health services as well as psychiatrists and paediatricians. Dr Anna Skinner, the Chief Clinical Advisor for Primary Care at Health New Zealand, told Checkpoint that the change would help eliminate barriers for people to get treatment. "People have been accessing private psychiatry at considerable personal costs," she said. Ritalin is one of several drugs that treat ADHD. Photo: CC 2.0 Health agencies have set the start date at 1 February 2026 to address potential supply issues related to methylphenidate or Ritalin, and to give more time for workforce preparation. However, not all GPs and nurse practitioners will be equipped to carry out the work immediately, so it will be important to talk to your physician about your options, Pharmac said. The assessments will not be done in your typical 15-minute GP visit and will possibly require multiple visits to specialised staff, Skinner said. "It's certainly not a 15-minute diagnosis so it's not something that everybody will be able to access the morning after the changes." In making the announcement Doocey said it was important to have consistency as the policy changes. "The Ministry of Health is working with sector representatives to develop a clinical principles framework for the assessment and treatment of ADHD. This will ensure there is quality and consistency for supporting patients with ADHD in New Zealand." Psilocybin, a chemical from certain mushrooms, has been used to treat depression. Photo: Pixabay Psilocybin is a chemical obtained from certain kinds of mushrooms. It's been used in spiritual rituals, recreationally and as medicine over the years - and picked up the tag "magic mushrooms". It's also become a possible treatment for depression, as psilocybin is believed to interact with serotonin receptors in the brain. Serotonin is a neurotransmitter which regulates mood and other bodily functions and is sometimes called "the happiness chemical". It will still be an unapproved medicine but available for clinical treatment for the first time outside of trials. "Psilocybin is a medicine that can treat untreatable depression," Seymour said in making the announcement. "It was first researched in the 1950s and '60s and more recently there's been extensive research and approvals by the FDA in the United States to be able to use these types of medicines." Australia made a similar move to allow prescriptions of it in clinical settings two years ago. However, initially its use will be very limited in New Zealand. Only one person at the moment in all of New Zealand - psychiatrist Dr Cameron Lacey, based in Christchurch. Speaking to RNZ recently he said it had taken "a long time, a lot of energy and perseverance" to get to the approval stage, which had taken around four years. The treatment isn't cheap in other countries, however - Dr Lacey said it could run from NZ$16,500 to NZ$40,000 for the course of psychotherapy and psilocybin sessions. He hoped it would be cheaper when it comes to New Zealand. "I'm hopeful we can work with Health New Zealand to create a funding pathway for those who have failed to respond to current standard treatments and endure significant symptoms to be able to get access to this treatment." The latest data from the New Zealand Drug Foundation shows the use of psychedelics - which includes substances such as LSD, psilocybin and ketamine - has doubled in the past six years. Dr Lacey will operate under strict reporting and record-keeping requirements, Seymour said. He hoped more psychiatrists would apply to use it. "If a doctor believes psilocybin can help, they should have the tools to try." Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

Death of MP Takutai Tarsh Kemp brings parliament together
Death of MP Takutai Tarsh Kemp brings parliament together

RNZ News

time8 hours ago

  • RNZ News

Death of MP Takutai Tarsh Kemp brings parliament together

te ao Maori 22 minutes ago The sudden death of MP Takutai Tarsh Kemp in the early hours of this morning has brought members from across the house together today. Flags in the capital have been flying at half mast for the Te Pati Maori MP for Tamaki Makarau, who was at parliament just yesterday. Takutai Tarsh Kemp, who recently celebrated her 50th birthday, revealed she was diagnosed with kidney disease last year. Acting political editor Craig McCulloch reports.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store